Nanomedicine News RSS Feed - Nanomedicine

NIH Awards Grant to Develop ‘Nanobombs’ to Treat Biofilm Infection in Chronic Wounds

NIH Awards Grant to Develop ‘Nanobombs’ to Treat Biofilm Infection in Chronic Wounds

The National Institutes of Health (NIH) has awarded Kent State University's Min-Ho Kim, Ph.D., assistant professor of biological sciences in the College of Arts and Sciences, a $1,842,350 five-year grant. The grant from the NIH's National Institute of Nursing Research is to develop "nanobombs," a nanotechnology-based therapeutic platform that can treat biofilm infection in chronic wounds. [More]
Mesoporous Particles Consisting Solely of Phospholipids for Drug Delivery

Mesoporous Particles Consisting Solely of Phospholipids for Drug Delivery

A research group at MANA, NIMS, succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system. [More]
Functional Surfaces of Gold Nanoparticles Act on Osteogenic Differentiation of Stem Cells

Functional Surfaces of Gold Nanoparticles Act on Osteogenic Differentiation of Stem Cells

Tissue Regeneration Materials Unit at MANA, NIMS successfully developed gold nanoparticles that have functional surfaces and act on osteogenic differentiation of stem cells. [More]
Global Market for Nanoparticles in Biotechnology and Pharmaceuticals Expected to Reach $79.8 Billion in 2019

Global Market for Nanoparticles in Biotechnology and Pharmaceuticals Expected to Reach $79.8 Billion in 2019

This BCC Research report provides detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women. The applicability of specific types of nanoparticles for specific applications is also discussed. CAGR projections are given from the period 2014 through 2019. [More]
Plasmons Influence Carbon-Based Nanoparticles for Sensitizing Cancerous Tumors

Plasmons Influence Carbon-Based Nanoparticles for Sensitizing Cancerous Tumors

Radiotherapy used in cancer treatment is a promising treatment method, albeit rather indiscriminate. Indeed, it affects neighbouring healthy tissues and tumours alike. Researchers have thus been exploring the possibilities of using various radio-sensitizers; these nanoscale entities focus the destructive effects of radiotherapy more specifically on tumour cells. [More]
A Nontoxic Nanocarrier for Targeted Delivery of Analogs to Cancer Cells

A Nontoxic Nanocarrier for Targeted Delivery of Analogs to Cancer Cells

Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic. [More]
Novel Microfluidic Chip Can Capture Rare Clusters of Circulating Tumor Cells

Novel Microfluidic Chip Can Capture Rare Clusters of Circulating Tumor Cells

Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads. The work was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health. [More]
Toxin-Absorbing Nanosponges in Gels Could Help Treat MRSA Infections

Toxin-Absorbing Nanosponges in Gels Could Help Treat MRSA Infections

Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials. [More]
NantPharma to Acquire Rights to Cynviloq Through Acquisition of Igdrasol

NantPharma to Acquire Rights to Cynviloq Through Acquisition of Igdrasol

Sorrento Therapeutics, Inc., announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the NantWorks ecosystem of companies, agreed to acquire the rights to Cynviloq through the acquisition of Igdrasol, Inc., a wholly-owned subsidiary of Sorrento, which has been developing Cynviloq (paclitaxel nanoparticle polymeric micelle) in a bio-equivalence trial. [More]
CCC Awards Grants to Test RNA Nanotherapy to Target MED1 in Breast Cancer Cells

CCC Awards Grants to Test RNA Nanotherapy to Target MED1 in Breast Cancer Cells

For the second year, the Cincinnati Cancer Center (CCC) has awarded $160,000 in pilot grants to members and basic scientists who are collaborating to find out more about various cancers with hopes of generating more data and additional funding. [More]
Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Park Systems - Manufacturer of a complete range of AFM solutions